Platelet Cut-Off for Anticoagulant Therapy in Thrombocytopenic Patients with Blood Cancer and Venous Thromboembolism
Venous thromboembolism (VTE) is a recurrent risk factor in cancer patients. In particular, patients with hematologic...
Guidelines and Tools
Making cancer-related complications and comorbidities an EU health priority: a joint statement from the European Thrombosis and Haemostasis Alliance (ETHA)
Cancer represents the second most important cause of death and morbidity in Europe, with more than 3.7 million new...
Venous thromboembolism in patients with solid tumors: the Italian Association of Medical Oncology (AIOM) guidelines 2019
The latest guidelines for venous thromboembolism in patients with solid tumors from the Italian Association of Medical...
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
The American Society of Clinical Oncology just published the new recommendations regarding VTE prophylaxis and...
Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy
Approximately 4% of cancer patients have non-valvular atrial fibrillation (NVAF) and require anticoagulation for...
Contemporary breast cancer treatment-associated venous thromboembolism
Breast cancer patients have a three-to four fold increased risk of venous thromboembolism (VTE) when compared to women...
DOACs in the treatment of cancer-associated thrombosis
Since the publication of the SELECT-D trial1 and the Hokusai-VTE Cancer study2, there has been a shift in the...
Managing antithrombotic medication in thrombocytopenia
Cancer is associated with an increased risk of venous but also arterial thrombosis1. Moreover, contemporary anticancer...